Remimazolam on the Incidence of Postoperative Acute Kidney Injury

Sponsor
Seoul National University Bundang Hospital
Study ID
NCT07674719
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Acute Kidney Injury
  • Fluid Therapy
  • Fluid Therapy DURING SURGERY
  • Hemodynamic Stability
  • Hepatobiliary Surgery
  • Propofol
  • Remimazolam

Eligibility Criteria

Sex
ALL
Age
19 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Remimazolam (Byfavo) — DRUG
    TCI of remimazolam (0.3 - 1.5 mcg/ml)
  • propofol — DRUG
    TCI of propofol (4.0 - 5.0 mg/mL)

Study Details

We hypothesized that in patients undergoing elective hepatobiliary-pancreatic surgery, the group in which anesthesia is induced and maintained with remimazolam during surgery would maintain hemodynamic stability and reduce the incidence of postoperative acute kidney injury compared to propofol. The purpose is to provide practical evidence for perioperative management differentiated from other surgeries for hepatobiliary-pancreatic surgery patients for whom intraoperative fluid therapy is restricted.

Key Dates

First listed
Jun 29, 2026
Start date
Jun 26, 2026
Status verified
Jun 2026
Primary completion
Jun 26, 2027
Completion
Jun 26, 2028

Study Design

Enrollment
78 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: Remimazolam
  • Active Comparator: Propofol

Primary Outcome Measure

Acute kidney injury [ Time Frame: preop, postop day 0, 1, 3, 5 ]

Central Contacts

Related Studies